Uyarıcılar (Amfetamin, Ekstazi, Kokain vb.) Kullanım Bozukluğu ve Ebelik Yaklaşımı
Referanslar
Ciccarone D. Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy. Prim Care. 2011; 38(1): 41-58. doi:10.1016/j.pop.2010.11.004.
MacKenzie RG, Heischober B. Methamphetamine. Pediatr Rev. 1997; 18(9): 305-309. doi:10.1542/pir.18-9-305.
Pfeiffer-Gerschel T, Schneider F, Dammer E, Braun B, Kraus L. Methamphetaminkonsum in Deutschland: Verbreitung und Problemlage. Sucht. 2019; 65(4): 241–249.
Mutlu E, Okudan M, Aşıcıoğlu F. Precursor Substances Used in Manufacturing Drug: Ten-Year Single Center Data. Turkiye Klinikleri Journal of Forensic Medicine and Forensic Sciences. 2020; 17(1): 25–34.
Cox S, Posner SF, Kourtis AP, Jamieson DJ. Hospitalizations with amphetamine abuse among pregnant women. Obstet Gynecol. 2008; 111(2 Pt 1): 341-347. doi:10.1097/01.AOG.000300377.82722.ad.
Terplan M, Smith EJ, Kozloski MJ, Pollack HA. Methamphetamine use among pregnant women. Obstet Gynecol. 2009; 113(6): 1285-1291. doi:10.1097/AOG.0b013e3181a5ec6f.
Pubill D, Canudas AM, Pallàs M, Camins A, Camarasa J, Escubedo E. Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity. Naunyn Schmiedebergs Arch Pharmacol. 2003; 367(5): 490-499. doi:10.1007/s00210-003-0747-y.
Chang X, Sun Y, Zhang Y, Muhai J, Lu L, Shi J. A Review of Risk Factors for Methamphetamine-Related Psychiatric Symptoms. Front Psychiatry. 2018; 9: 603. doi:10.3389/fpsyt.2018.00603
Panenka WJ, Procyshyn RM, Lecomte T, MacEwan GW, Flynn SW, Honer WG, et al. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend. 2013; 129(3): 167-179. doi:10.1016/j.drugalcdep.2012.11.016.
Jayanthi S, Daiwile AP, Cadet JL. Neurotoxicity of methamphetamine: Main effects and mechanisms. Exp Neurol. 2021; 344: 113795. doi:10.1016/j.expneurol.2021.113795.
Wright TE, Schuetter R, Tellei J, Sauvage L. Methamphetamines and pregnancy outcomes. J Addict Med. 2015; 9(2): 111-117. doi:10.1097/ADM.0000000000000101.
Shah R, Diaz SD, Arria A, LaGasse LL, Derauf C, Newman E, et al. Prenatal methamphetamine exposure and short-term maternal and infant medical outcomes. Am J Perinatol. 2012; 29(5): 391.
Derauf C, LaGasse LL, Smith LM, Grant M, Shah R, Arria A, et al. Demographic and psychosocial characteristics of mothers using methamphetamine during pregnancy: preliminary results of the infant development, environment, and lifestyle study (IDEAL). The American Journal of Drug and Alcohol Abuse. 2007; 33(2): 281–289.
Poulton R, Caspi A, Milne BJ, Thomson WM, Taylor A, Sears MR, et al. Association between children’s experience of socioeconomic disadvantage and adult health: a life-course study. The Lancet. 2002; 360(9346): 1640–1645.
Afifi TO, Enns MW, Cox BJ, Asmundson GJG, Stein MB, Sareen J.Population Attributable Fractions of Psychiatric Disorders and Suicide Ideation and Attempts Associated With Adverse Childhood Experiences. Am J Public Health. 2008; 98(5): 946–952.
Hasin DS, O'Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, et al. DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry. 2013; 170(8): 834-851. doi:10.1176/appi.ajp.2013.12060782.
Newton TF, Roache JD, De La Garza R 2nd, Fong T, L Wallace CL, Li SH, et al. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology. 2006; 31(7): 1537-1544. doi:10.1038/sj.npp.1300979.
Oei J, Abdel-Latif ME, Clark R, Craig F, Lui K. Short-term outcomes of mothers and infants exposed to antenatal amphetamines. Arch Dis Child Fetal Neonatal Ed. 2010; 95(1): 36-41. doi:10.1136/adc.2008.157305.
Good MM, Solt I, Acuna JG, Rotmensch S, Kim MJ. Methamphetamine use during pregnancy: maternal and neonatal implications. Obstet Gynecol. 2010; 116(2 Pt 1): 330-334. doi:10.1097/AOG.0b013e3181e67094.
Kalaitzopoulos DR, Chatzistergiou K, Amylidi AL, Kokkinidis DG, Goulis DG. Effect of Methamphetamine Hydrochloride on Pregnancy Outcome: A Systematic Review and Meta-analysis. J Addict Med. 2018; 12(3): 220-226. doi:10.1097/ADM.0000000000000391.
Gilbert EF, Khoury GH. Dextroamphetamine and congenital cardiac malformations. The Journal of Pediatrics. 1970; 76(4): 638.
Matera R, Zabala H, Jimenez A. Bifid exencephalia. Teratogen action of amphetamine. Int Surg. 1968; 50(1): 79.
Little BB, Snell LM. Methamphetamine abuse during pregnancy: outcome and fetal effects. Obstet Gynecol. 1988; 72(4): 541–544.
Smith L, Yonekura ML, Wallace T, Berman N, Kuo J, Berkowitz C. Effects of prenatal methamphetamine exposure on fetal growth and drug withdrawal symptoms in infants born at term. J Dev Behav Pediatr. 2003; 24(1): 17–23.
Chang L, Smith LM, LoPresti C, Yunekura ML, Kuo J, Walot I, et al. Smaller subcortical volumes and cognitive deficits in children with prenatal methamphetamine exposure. Psychiatry Research: Neuroimaging. 2004; 132(2): 95–106.
Warton FL, Meintjes EM, Warton CMR, Molteno CD, Lindinger NM, Carter RC, et al. Prenatal methamphetamine exposure is associated with reduced subcortical volumes in neonates. Neurotoxicol Teratol. 2018;65:51-59. doi:10.1016/j.ntt.2017.10.005. Psychiatry Research: Neuroimaging. 2004; 132(2): 95–106.
Kiblawi ZN, Smith LM, Diaz SD, LaGasse LL, Derauf C, Newman E, et al. Prenatal methamphetamine exposure and neonatal and infant neurobehavioral outcome: results from the IDEAL study. Subst Abus. 2014; 35(1): 68–73.
Smith LM, Paz MS, LaGasse LL, Derauf C, Newman E, Shah R, et al. Maternal depression and prenatal exposure to methamphetamine: neurodevelopmental findings from the infant development, environment, and lifestyle (ideal) study. Depress Anxiety. 2012; 29(6): 515–522.
Bartu A, Dusci LJ, Ilett KF. Transfer of methylamphetamine and amphetamine into breast milk following recreational use of methylamphetamine. Br J Clin Pharmacol. 2009; 67(4): 455–459.
Gold MS, Washton AM, Dackis CA. Cocaine abuse: Neurochemistry, phenomenology, and treatment. NIDA Research Monograph. 1985; 61: 130–150.
Ögel K. Bağımlılık Yapan Maddeler. In: Sigara, Alkol ve Madde Kullanım bozuklukları: Tanı, Tedavi ve Önleme. İstanbul: Yeniden Yayınları. 2010; pp. 53–55.
Rodriguez JJ, Smith VC. Epidemiology of perinatal substance use: Exploring trends in maternal substance use. Semin Fetal Neonatal Med. 2019; 24(2): 86-89. doi:10.1016/j.siny.2019.01.006
Türkiye Uyuşturucu Raporu. 2020. Erişim adresi: https://www.narkotik.pol.tr/kurumlar/narkotik.pol.tr/TUB%C4%B0M/TU%CC%88RKI%CC%87YE-UYUS%CC%A7TURUCU-RAPORU_26-HAZI%CC%87RAN-FI%CC%87NAL-_1_.pdf. pp. 33–66 Erişim tarihi: 18.07.2024.
Avrupa Uyuşturucu ve Uyuşturucu Bağımlılığını İzleme Merkezi. Avrupa Uyuşturucu Raporu Eğilimler ve Gelişmeler. 2020. Erişim adresi: https://www.narkotik.pol.tr/kurumlar/narkotik.pol.tr/TUB%C4%B0M/Uluslar-Arasi-Yayinlar/EUROPEAN-DRUG-REPORT-2020-TURKCE.pdf. Erişim Tarihi: 18.07.2024.
Sun L, Wang H. Acupuncture in the treatment of cocaine addiction: how does it work?. Acupunct Med. 2024; 42(5): 251-259. doi:10.1177/09645284241248473.
White SM, Lambe CJ. The pathophysiology of cocaine abuse. J Clin Forensic Med. 2003; 10(1): 27-39. doi:10.1016/S1353-1131(03)00003-8.
Günal YH. Uyuşturucu Madde Suçları, Ankara: Kazancı Yayınları.1976.p.26
Arıkan Z. Kokain Kullanımına Bağlı Ruhsal ve Davranışsal Bozukluklar. Madde Bağımlılığı Tanı ve Tedavi Kılavuzu El Kitabı içinde. 2012; pp.147-154. Ankara: T.C. Sağlık Bakanlığı Sağlık Hizmetleri Genel Müdürlüğü. Erişim adresi: https://ekutuphane.saglik.gov.tr/Ekutuphane/kitaplar/maddebagimliligi.pdf. Erişim Tarihi: 18.07.2024
Çeliker A, Bolat D. Bağımlılık yapan maddelerin gebelik döneminde kullanımının değerlendirilmesi. FABAD J. Pharm. Sci. 2021; 46(2): 225-250.
Krishna RB, Levitz M, Dancis J. Transfer of cocaine by the perfused human placenta: the effect of binding to serum proteins. Am J Obstet Gynecol. 1993; 169(6): 1418–1423.
Singer L, Arendt RE, Minnes S, Garber RM. Medical and Psychologic Risks of Maternal Cocaine Use. Resid Staff Physician. 1997; 43(10): 55-65.
Sheinkopf SJ, Lagasse LL, Lester BM, Liu J, Seifer R, Bauer CR, et al. Prenatal cocaine exposure: cardiorespiratory function and resilience. Ann N Y Acad Sci. 2006; 1094(1): 354–358.
Sadock BJ, Saddock VA. Kaplan, Sadock’s. Comprehensive Textbook of Psychiatry. (Ali Bozkurt & Ercan Dalbudak Çev.Ed.) Güneş Tıp Kitabevi; 2022. pp.1280-1290.
Palazón-Llecha A, Caparrós B, Trujols J, Duran-Sindreu S, Batlle F, Madre M, et al. Predictors of cocaine use disorder treatment outcomes: a systematic review. Systematic Reviews. 2024; 13(1): 124. doi:10.1186/s13643-024-02550-z.
Akan M, Cumurcu HB. Kokain ile İlişkili Patolojiler. Current Addiction Research. 2021; 5(1): 16-24. doi:10.5455/car.105-1632808119.
Chavkin W. Cocaine and pregnancy—time to look at the evidence. JAMA. 2001; 285(12): 1626–1628.
Woods JR, Plessinger MA. Pregnancy increases cardiovascular toxicity to cocaine. Am J Obstet Gynecol. 1990; 162(2): 529–533.
Plessinger MA, Woods JR. Progesterone increases cardiovascular toxicity to cocaine in nonpregnant ewes. Am J Obstet Gynecol. 1990; 163(5): 1659–1664.
Kuczkowski KM. Anesthetic implications of drug abuse in pregnancy. J Clin Anesth. 2003; 15(5): 382–394.
Hoyme HE, Jones KL, Dixon SD, Jewett T, Hanson JW, Robinson LK, et al. Prenatal cocaine exposure and fetal vascular disruption. Pediatrics. 1990; 85(5): 743–747.
Gouin K, Murphy K, Shah PS. Effects of cocaine use during pregnancy on low birthweight and preterm birth: systematic review and metaanalyses. Am J Obstet Gynecol. 2011; 204(4): 340-342.
Bauer CR, Langer JC, Shankaran S, Bada HS, Lester B, Wright LL, et al. Acute neonatal effects of cocaine exposure during pregnancy. Arch Pediatr Adolesc Med. 2005; 159(9): 824–834.
Gonsoulin W, Borge D, Moise KJ. Rupture of unscarred uterus in primigravid woman in association with cocaine abuse. Am J Obstet Gynecol. 1990; 163(2): 526–527.
Fares I, McCulloch KM, Raju T. Intrauterine cocaine exposure and the risk for sudden infant death syndrome: a meta-analysis Journal of Perinatology : Official Journal of the California Perinatal Association, 1997; 17(3): 179-182.
Committee Opinion No. 711: Opioid use and opioid use disorder in pregnancy. Obstet Gynecol. 2017; 130(2): 81–84.
Smid MC, Metz TD, Gordon AJ. Stimulant use in pregnancy: an under-recognized epidemic among pregnant women. Clin Obstet Gynecol. 2019; 62(1): 168-184. doi:10.1097/GRF.0000000000000418.
Singer L, Arendt R, Farkas K, Minnes S, Huang J, Yamashita T. Relationship of prenatal cocaine exposure and maternal postpartum psychological distress to child developmental outcome. Dev Psychopathol. 1997; 9(3): 473–489.
Accornero VH, Anthony JC, Morrow CE, Xue L, Mansoor E, Johnson AL, et al. Estimated effect of prenatal cocaine exposure on examiner-rated behavior at age 7 years. Neurotoxicol Teratol. 2011; 33(3): 370–378.
Bridgett DJ, Mayes LC. Development of inhibitory control among prenatally cocaine exposed and non-cocaine exposed youths from late childhood to early adolescence: The effects of gender and risk and subsequent aggressive behavior. Neurotoxicol Teratol. 2011; 33(1): 47–60.
Aghamohammadi A, Zafari M. Crack abuse during pregnancy: maternal, fetal and neonatal complication. J Matern Fetal Neonatal Med. 2016; 29(5): 795-797. doi:10.3109/14767058.2015.1018821.
Klie KA, Nagle-Yang S, Zhao L, Fringuello ME. Integrated care for pregnant and parenting people with substance use. Clin Obstet Gynecol. 2024; 67(1): 200-221. doi:10.1097/GRF.0000000000000831.
Bresnahan K, Brooks C, Zuckerman B. Prenatal cocaine use: impact on infants and mothers. Pediatr Nurs. 1991; 17(2): 123-129.
Çirkin M. Kullanmak için uyuşturucu veya uyarıcı madde satın almak, kabul etmek veya bulundurmak ya da uyuşturucu veya uyarıcı madde kullanmak suçu. T.C. Dokuz Eylül Üniversitesi Sosyal Bilimler Enstitüsü Kamu Hukuku Anabilim Dalı Kamu Hukuku Programı Yüksek Lisans Tezi. İzmir, 2020.
Ögel K. Sigara, Alkol ve Madde Kullanım Bozuklukları: Tanı, Tedavi ve Önleme. İstanbul: Yeniden Yayınları; 2010. pp. 3-39.
KitaSinger LT, Moore DG, Fulton S, Goodwin J, Turner JD, Min MO, et al. Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy. Neurotoxicol Teratol. 2012; 34(3): 303–310.
Landry MJ. MDMA: a review of epidemiological data. J Psychoactive Drugs. 2002; 34(2): 163–169.
Van Tonningen MR, Garbis H, Reuvers M. Ecstasy exposure during pregnancy. Teratology. 1998; 58: 33A.
Singer LT, Moore DG, Min MO, Goodwin J, Turner JD, Fulton S, et al. Developmental outcomes of 3, 4-methylenedioxymethamphetamine (ecstasy)-exposed infants in the UK. Human Psychopharmacology: Clinical and Experimental. 2015; 30(4): 290–294.
Singer LT, Moore DG, Min MO, Goodwin J, Turner JD, Fulton S, et al. Motor delays in MDMA (ecstasy) exposed infants persist to 2 years. Neurotoxicol Teratol. 2016; 54: 22–28.
Samenuk D, Link MS, Homoud MK, Contreras R, Theoharides TC, Wang PJ, et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Paper presented at: Mayo Clinic Proceedings. 2002
Maglione M, Miotto K, Iguchi M, Jungvig L, Morton SC, Shekelle PG. Psychiatric effects of ephedra use: an analysis of food and drug administration reports of adverse events. Am J Psychiatry. 2005; 162(1): 189–191.
Kennedy J. Herb and supplement use in the US adult population. Clin Ther. 2005; 27(11): 1847–1858.
Broussard CS, Louik C, Honein MA, Mitchell AA, Study NBDP. Herbal use before and during pregnancy. Am J Obstet Gynecol. 2010; 202(5): 443e1–443e6.
Bitsko RH, Reefhuis J, Louik C, Werler M, Feldkamp ML, Waller DK, et al. Periconceptional use of weight loss products including ephedra and the association with birth defects. Birth Defects Research Part A: Clinical and Molecular Teratology. 2008; 82(8): 553–562.
Chen S, Zhou W, Lai M. Synthetic Cathinones: Epidemiology, Toxicity, Potential for Abuse, and Current Public Health Perspective. Brain Sci. 2024; 14(4): 334. doi:10.3390/brainsci14040334.
Angoa-Perez M, Kuhn DM. The pharmacology and neurotoxicology of synthetic cathinones. Adv Pharmacol. 2024; 99: 61-82. doi:10.1016/bs.apha.2023.12.001.
Miller BL, Stogner JM, Miller JM, Fernandez MI. The arrest and synthetic novel psychoactive drug relationship: Observations from a young adult population. Journal of Drug Issues. 2017; 47(1): 91–103.
John ME, Thomas-Rozea C, Hahn D. Bath salts abuse leading to new-onset psychosis and potential for violence. Clin Schizophr Relat Psychoses. 2017; 11(2): 120–124.
Miotto K, Striebel J, Cho AK, Wang C. Clinical and pharmacological aspects of bath salt use: a review of the literature and case reports. Drug Alcohol Depend. 2013; 132(1–2): 1–12.
Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, et al. Powerful cocaine-like actions of 3, 4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology. 2013; 38(4): 552.
Khawaja M, Al-Nsour M, Saad G. Khat (Catha edulis) chewing during pregnancy in Yemen: findings from a national population survey. Maternal and Child Health Journal. 2008; 12(3): 308–312.
Nakajima M, Jebena MG, Taha M, Tesfaye M, Gudina E, Lemieux A, et al. Correlates of khat use during pregnancy: A cross-sectional study. Addict Behav. 2017; 73: 178–184.
Kristiansson B, Abdul Ghani N, Eriksson M, Garle M, Qirbi A. Use of khat in lactating women: a pilot study on breast-milk secretion. J Ethnopharmacol. 1987; 21(1): 85–90.
Ibrahim Ali Omer M, Mansoub MA, Omer R, Omer R, Shadli M, Williams R. The effect of qat chewing and other factors on breast-feeding and child survival in a Yemeni society. Sudanese Journal of Paediatrics. 2011; 11(2): 14–20.
Geraghty S, Doleman G, De Leo A. Midwives' attitudes towards pregnant women using substances: Informing a care pathway. Women Birth. 2019; 32(4): 477-482. doi:10.1016/j.wombi.2018.09.007.
Economidoy E, Klimi A, Vivilaki VG. Caring for substance abuse pregnant women: The role of the midwife. Health Science Journal. 2012; 6(1): 161.
Geraghty S, Doleman G, De Leo A. Midwives' attitudes towards pregnant women using substances: Informing a care pathway. Women Birth. 2019; 32(4): 477-482. doi:10.1016/j.wombi.2018.09.007.
Stephany Theresa M. The pregnant addict: treat or prosecute?: Implications for midwifery management. Journal of Nurse-Midwifery. 1999; 44(2): 154-156.
Figurasin R, Lee VR, Maguire NJ. 3,4-Methylenedioxymethamphetamine (MDMA) Toxicity. In: StatPearls. Treasure Island (FL): StatPearls Publishing; January 17, 2024. Erişim adresi: https://www.ncbi.nlm.nih.gov/books/NBK538482/ Erişim tarihi: 18.07.2024
Baldo BA. The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns. Arch Toxicol. 2024; 98(8): 2409-2427. doi:10.1007/s00204-024-03765-8.
MacKenzie RG, Heischober B. Methamphetamine. Pediatr Rev. 1997; 18(9): 305-309. doi:10.1542/pir.18-9-305.
Pfeiffer-Gerschel T, Schneider F, Dammer E, Braun B, Kraus L. Methamphetaminkonsum in Deutschland: Verbreitung und Problemlage. Sucht. 2019; 65(4): 241–249.
Mutlu E, Okudan M, Aşıcıoğlu F. Precursor Substances Used in Manufacturing Drug: Ten-Year Single Center Data. Turkiye Klinikleri Journal of Forensic Medicine and Forensic Sciences. 2020; 17(1): 25–34.
Cox S, Posner SF, Kourtis AP, Jamieson DJ. Hospitalizations with amphetamine abuse among pregnant women. Obstet Gynecol. 2008; 111(2 Pt 1): 341-347. doi:10.1097/01.AOG.000300377.82722.ad.
Terplan M, Smith EJ, Kozloski MJ, Pollack HA. Methamphetamine use among pregnant women. Obstet Gynecol. 2009; 113(6): 1285-1291. doi:10.1097/AOG.0b013e3181a5ec6f.
Pubill D, Canudas AM, Pallàs M, Camins A, Camarasa J, Escubedo E. Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity. Naunyn Schmiedebergs Arch Pharmacol. 2003; 367(5): 490-499. doi:10.1007/s00210-003-0747-y.
Chang X, Sun Y, Zhang Y, Muhai J, Lu L, Shi J. A Review of Risk Factors for Methamphetamine-Related Psychiatric Symptoms. Front Psychiatry. 2018; 9: 603. doi:10.3389/fpsyt.2018.00603
Panenka WJ, Procyshyn RM, Lecomte T, MacEwan GW, Flynn SW, Honer WG, et al. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend. 2013; 129(3): 167-179. doi:10.1016/j.drugalcdep.2012.11.016.
Jayanthi S, Daiwile AP, Cadet JL. Neurotoxicity of methamphetamine: Main effects and mechanisms. Exp Neurol. 2021; 344: 113795. doi:10.1016/j.expneurol.2021.113795.
Wright TE, Schuetter R, Tellei J, Sauvage L. Methamphetamines and pregnancy outcomes. J Addict Med. 2015; 9(2): 111-117. doi:10.1097/ADM.0000000000000101.
Shah R, Diaz SD, Arria A, LaGasse LL, Derauf C, Newman E, et al. Prenatal methamphetamine exposure and short-term maternal and infant medical outcomes. Am J Perinatol. 2012; 29(5): 391.
Derauf C, LaGasse LL, Smith LM, Grant M, Shah R, Arria A, et al. Demographic and psychosocial characteristics of mothers using methamphetamine during pregnancy: preliminary results of the infant development, environment, and lifestyle study (IDEAL). The American Journal of Drug and Alcohol Abuse. 2007; 33(2): 281–289.
Poulton R, Caspi A, Milne BJ, Thomson WM, Taylor A, Sears MR, et al. Association between children’s experience of socioeconomic disadvantage and adult health: a life-course study. The Lancet. 2002; 360(9346): 1640–1645.
Afifi TO, Enns MW, Cox BJ, Asmundson GJG, Stein MB, Sareen J.Population Attributable Fractions of Psychiatric Disorders and Suicide Ideation and Attempts Associated With Adverse Childhood Experiences. Am J Public Health. 2008; 98(5): 946–952.
Hasin DS, O'Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, et al. DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry. 2013; 170(8): 834-851. doi:10.1176/appi.ajp.2013.12060782.
Newton TF, Roache JD, De La Garza R 2nd, Fong T, L Wallace CL, Li SH, et al. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology. 2006; 31(7): 1537-1544. doi:10.1038/sj.npp.1300979.
Oei J, Abdel-Latif ME, Clark R, Craig F, Lui K. Short-term outcomes of mothers and infants exposed to antenatal amphetamines. Arch Dis Child Fetal Neonatal Ed. 2010; 95(1): 36-41. doi:10.1136/adc.2008.157305.
Good MM, Solt I, Acuna JG, Rotmensch S, Kim MJ. Methamphetamine use during pregnancy: maternal and neonatal implications. Obstet Gynecol. 2010; 116(2 Pt 1): 330-334. doi:10.1097/AOG.0b013e3181e67094.
Kalaitzopoulos DR, Chatzistergiou K, Amylidi AL, Kokkinidis DG, Goulis DG. Effect of Methamphetamine Hydrochloride on Pregnancy Outcome: A Systematic Review and Meta-analysis. J Addict Med. 2018; 12(3): 220-226. doi:10.1097/ADM.0000000000000391.
Gilbert EF, Khoury GH. Dextroamphetamine and congenital cardiac malformations. The Journal of Pediatrics. 1970; 76(4): 638.
Matera R, Zabala H, Jimenez A. Bifid exencephalia. Teratogen action of amphetamine. Int Surg. 1968; 50(1): 79.
Little BB, Snell LM. Methamphetamine abuse during pregnancy: outcome and fetal effects. Obstet Gynecol. 1988; 72(4): 541–544.
Smith L, Yonekura ML, Wallace T, Berman N, Kuo J, Berkowitz C. Effects of prenatal methamphetamine exposure on fetal growth and drug withdrawal symptoms in infants born at term. J Dev Behav Pediatr. 2003; 24(1): 17–23.
Chang L, Smith LM, LoPresti C, Yunekura ML, Kuo J, Walot I, et al. Smaller subcortical volumes and cognitive deficits in children with prenatal methamphetamine exposure. Psychiatry Research: Neuroimaging. 2004; 132(2): 95–106.
Warton FL, Meintjes EM, Warton CMR, Molteno CD, Lindinger NM, Carter RC, et al. Prenatal methamphetamine exposure is associated with reduced subcortical volumes in neonates. Neurotoxicol Teratol. 2018;65:51-59. doi:10.1016/j.ntt.2017.10.005. Psychiatry Research: Neuroimaging. 2004; 132(2): 95–106.
Kiblawi ZN, Smith LM, Diaz SD, LaGasse LL, Derauf C, Newman E, et al. Prenatal methamphetamine exposure and neonatal and infant neurobehavioral outcome: results from the IDEAL study. Subst Abus. 2014; 35(1): 68–73.
Smith LM, Paz MS, LaGasse LL, Derauf C, Newman E, Shah R, et al. Maternal depression and prenatal exposure to methamphetamine: neurodevelopmental findings from the infant development, environment, and lifestyle (ideal) study. Depress Anxiety. 2012; 29(6): 515–522.
Bartu A, Dusci LJ, Ilett KF. Transfer of methylamphetamine and amphetamine into breast milk following recreational use of methylamphetamine. Br J Clin Pharmacol. 2009; 67(4): 455–459.
Gold MS, Washton AM, Dackis CA. Cocaine abuse: Neurochemistry, phenomenology, and treatment. NIDA Research Monograph. 1985; 61: 130–150.
Ögel K. Bağımlılık Yapan Maddeler. In: Sigara, Alkol ve Madde Kullanım bozuklukları: Tanı, Tedavi ve Önleme. İstanbul: Yeniden Yayınları. 2010; pp. 53–55.
Rodriguez JJ, Smith VC. Epidemiology of perinatal substance use: Exploring trends in maternal substance use. Semin Fetal Neonatal Med. 2019; 24(2): 86-89. doi:10.1016/j.siny.2019.01.006
Türkiye Uyuşturucu Raporu. 2020. Erişim adresi: https://www.narkotik.pol.tr/kurumlar/narkotik.pol.tr/TUB%C4%B0M/TU%CC%88RKI%CC%87YE-UYUS%CC%A7TURUCU-RAPORU_26-HAZI%CC%87RAN-FI%CC%87NAL-_1_.pdf. pp. 33–66 Erişim tarihi: 18.07.2024.
Avrupa Uyuşturucu ve Uyuşturucu Bağımlılığını İzleme Merkezi. Avrupa Uyuşturucu Raporu Eğilimler ve Gelişmeler. 2020. Erişim adresi: https://www.narkotik.pol.tr/kurumlar/narkotik.pol.tr/TUB%C4%B0M/Uluslar-Arasi-Yayinlar/EUROPEAN-DRUG-REPORT-2020-TURKCE.pdf. Erişim Tarihi: 18.07.2024.
Sun L, Wang H. Acupuncture in the treatment of cocaine addiction: how does it work?. Acupunct Med. 2024; 42(5): 251-259. doi:10.1177/09645284241248473.
White SM, Lambe CJ. The pathophysiology of cocaine abuse. J Clin Forensic Med. 2003; 10(1): 27-39. doi:10.1016/S1353-1131(03)00003-8.
Günal YH. Uyuşturucu Madde Suçları, Ankara: Kazancı Yayınları.1976.p.26
Arıkan Z. Kokain Kullanımına Bağlı Ruhsal ve Davranışsal Bozukluklar. Madde Bağımlılığı Tanı ve Tedavi Kılavuzu El Kitabı içinde. 2012; pp.147-154. Ankara: T.C. Sağlık Bakanlığı Sağlık Hizmetleri Genel Müdürlüğü. Erişim adresi: https://ekutuphane.saglik.gov.tr/Ekutuphane/kitaplar/maddebagimliligi.pdf. Erişim Tarihi: 18.07.2024
Çeliker A, Bolat D. Bağımlılık yapan maddelerin gebelik döneminde kullanımının değerlendirilmesi. FABAD J. Pharm. Sci. 2021; 46(2): 225-250.
Krishna RB, Levitz M, Dancis J. Transfer of cocaine by the perfused human placenta: the effect of binding to serum proteins. Am J Obstet Gynecol. 1993; 169(6): 1418–1423.
Singer L, Arendt RE, Minnes S, Garber RM. Medical and Psychologic Risks of Maternal Cocaine Use. Resid Staff Physician. 1997; 43(10): 55-65.
Sheinkopf SJ, Lagasse LL, Lester BM, Liu J, Seifer R, Bauer CR, et al. Prenatal cocaine exposure: cardiorespiratory function and resilience. Ann N Y Acad Sci. 2006; 1094(1): 354–358.
Sadock BJ, Saddock VA. Kaplan, Sadock’s. Comprehensive Textbook of Psychiatry. (Ali Bozkurt & Ercan Dalbudak Çev.Ed.) Güneş Tıp Kitabevi; 2022. pp.1280-1290.
Palazón-Llecha A, Caparrós B, Trujols J, Duran-Sindreu S, Batlle F, Madre M, et al. Predictors of cocaine use disorder treatment outcomes: a systematic review. Systematic Reviews. 2024; 13(1): 124. doi:10.1186/s13643-024-02550-z.
Akan M, Cumurcu HB. Kokain ile İlişkili Patolojiler. Current Addiction Research. 2021; 5(1): 16-24. doi:10.5455/car.105-1632808119.
Chavkin W. Cocaine and pregnancy—time to look at the evidence. JAMA. 2001; 285(12): 1626–1628.
Woods JR, Plessinger MA. Pregnancy increases cardiovascular toxicity to cocaine. Am J Obstet Gynecol. 1990; 162(2): 529–533.
Plessinger MA, Woods JR. Progesterone increases cardiovascular toxicity to cocaine in nonpregnant ewes. Am J Obstet Gynecol. 1990; 163(5): 1659–1664.
Kuczkowski KM. Anesthetic implications of drug abuse in pregnancy. J Clin Anesth. 2003; 15(5): 382–394.
Hoyme HE, Jones KL, Dixon SD, Jewett T, Hanson JW, Robinson LK, et al. Prenatal cocaine exposure and fetal vascular disruption. Pediatrics. 1990; 85(5): 743–747.
Gouin K, Murphy K, Shah PS. Effects of cocaine use during pregnancy on low birthweight and preterm birth: systematic review and metaanalyses. Am J Obstet Gynecol. 2011; 204(4): 340-342.
Bauer CR, Langer JC, Shankaran S, Bada HS, Lester B, Wright LL, et al. Acute neonatal effects of cocaine exposure during pregnancy. Arch Pediatr Adolesc Med. 2005; 159(9): 824–834.
Gonsoulin W, Borge D, Moise KJ. Rupture of unscarred uterus in primigravid woman in association with cocaine abuse. Am J Obstet Gynecol. 1990; 163(2): 526–527.
Fares I, McCulloch KM, Raju T. Intrauterine cocaine exposure and the risk for sudden infant death syndrome: a meta-analysis Journal of Perinatology : Official Journal of the California Perinatal Association, 1997; 17(3): 179-182.
Committee Opinion No. 711: Opioid use and opioid use disorder in pregnancy. Obstet Gynecol. 2017; 130(2): 81–84.
Smid MC, Metz TD, Gordon AJ. Stimulant use in pregnancy: an under-recognized epidemic among pregnant women. Clin Obstet Gynecol. 2019; 62(1): 168-184. doi:10.1097/GRF.0000000000000418.
Singer L, Arendt R, Farkas K, Minnes S, Huang J, Yamashita T. Relationship of prenatal cocaine exposure and maternal postpartum psychological distress to child developmental outcome. Dev Psychopathol. 1997; 9(3): 473–489.
Accornero VH, Anthony JC, Morrow CE, Xue L, Mansoor E, Johnson AL, et al. Estimated effect of prenatal cocaine exposure on examiner-rated behavior at age 7 years. Neurotoxicol Teratol. 2011; 33(3): 370–378.
Bridgett DJ, Mayes LC. Development of inhibitory control among prenatally cocaine exposed and non-cocaine exposed youths from late childhood to early adolescence: The effects of gender and risk and subsequent aggressive behavior. Neurotoxicol Teratol. 2011; 33(1): 47–60.
Aghamohammadi A, Zafari M. Crack abuse during pregnancy: maternal, fetal and neonatal complication. J Matern Fetal Neonatal Med. 2016; 29(5): 795-797. doi:10.3109/14767058.2015.1018821.
Klie KA, Nagle-Yang S, Zhao L, Fringuello ME. Integrated care for pregnant and parenting people with substance use. Clin Obstet Gynecol. 2024; 67(1): 200-221. doi:10.1097/GRF.0000000000000831.
Bresnahan K, Brooks C, Zuckerman B. Prenatal cocaine use: impact on infants and mothers. Pediatr Nurs. 1991; 17(2): 123-129.
Çirkin M. Kullanmak için uyuşturucu veya uyarıcı madde satın almak, kabul etmek veya bulundurmak ya da uyuşturucu veya uyarıcı madde kullanmak suçu. T.C. Dokuz Eylül Üniversitesi Sosyal Bilimler Enstitüsü Kamu Hukuku Anabilim Dalı Kamu Hukuku Programı Yüksek Lisans Tezi. İzmir, 2020.
Ögel K. Sigara, Alkol ve Madde Kullanım Bozuklukları: Tanı, Tedavi ve Önleme. İstanbul: Yeniden Yayınları; 2010. pp. 3-39.
KitaSinger LT, Moore DG, Fulton S, Goodwin J, Turner JD, Min MO, et al. Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy. Neurotoxicol Teratol. 2012; 34(3): 303–310.
Landry MJ. MDMA: a review of epidemiological data. J Psychoactive Drugs. 2002; 34(2): 163–169.
Van Tonningen MR, Garbis H, Reuvers M. Ecstasy exposure during pregnancy. Teratology. 1998; 58: 33A.
Singer LT, Moore DG, Min MO, Goodwin J, Turner JD, Fulton S, et al. Developmental outcomes of 3, 4-methylenedioxymethamphetamine (ecstasy)-exposed infants in the UK. Human Psychopharmacology: Clinical and Experimental. 2015; 30(4): 290–294.
Singer LT, Moore DG, Min MO, Goodwin J, Turner JD, Fulton S, et al. Motor delays in MDMA (ecstasy) exposed infants persist to 2 years. Neurotoxicol Teratol. 2016; 54: 22–28.
Samenuk D, Link MS, Homoud MK, Contreras R, Theoharides TC, Wang PJ, et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Paper presented at: Mayo Clinic Proceedings. 2002
Maglione M, Miotto K, Iguchi M, Jungvig L, Morton SC, Shekelle PG. Psychiatric effects of ephedra use: an analysis of food and drug administration reports of adverse events. Am J Psychiatry. 2005; 162(1): 189–191.
Kennedy J. Herb and supplement use in the US adult population. Clin Ther. 2005; 27(11): 1847–1858.
Broussard CS, Louik C, Honein MA, Mitchell AA, Study NBDP. Herbal use before and during pregnancy. Am J Obstet Gynecol. 2010; 202(5): 443e1–443e6.
Bitsko RH, Reefhuis J, Louik C, Werler M, Feldkamp ML, Waller DK, et al. Periconceptional use of weight loss products including ephedra and the association with birth defects. Birth Defects Research Part A: Clinical and Molecular Teratology. 2008; 82(8): 553–562.
Chen S, Zhou W, Lai M. Synthetic Cathinones: Epidemiology, Toxicity, Potential for Abuse, and Current Public Health Perspective. Brain Sci. 2024; 14(4): 334. doi:10.3390/brainsci14040334.
Angoa-Perez M, Kuhn DM. The pharmacology and neurotoxicology of synthetic cathinones. Adv Pharmacol. 2024; 99: 61-82. doi:10.1016/bs.apha.2023.12.001.
Miller BL, Stogner JM, Miller JM, Fernandez MI. The arrest and synthetic novel psychoactive drug relationship: Observations from a young adult population. Journal of Drug Issues. 2017; 47(1): 91–103.
John ME, Thomas-Rozea C, Hahn D. Bath salts abuse leading to new-onset psychosis and potential for violence. Clin Schizophr Relat Psychoses. 2017; 11(2): 120–124.
Miotto K, Striebel J, Cho AK, Wang C. Clinical and pharmacological aspects of bath salt use: a review of the literature and case reports. Drug Alcohol Depend. 2013; 132(1–2): 1–12.
Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, et al. Powerful cocaine-like actions of 3, 4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology. 2013; 38(4): 552.
Khawaja M, Al-Nsour M, Saad G. Khat (Catha edulis) chewing during pregnancy in Yemen: findings from a national population survey. Maternal and Child Health Journal. 2008; 12(3): 308–312.
Nakajima M, Jebena MG, Taha M, Tesfaye M, Gudina E, Lemieux A, et al. Correlates of khat use during pregnancy: A cross-sectional study. Addict Behav. 2017; 73: 178–184.
Kristiansson B, Abdul Ghani N, Eriksson M, Garle M, Qirbi A. Use of khat in lactating women: a pilot study on breast-milk secretion. J Ethnopharmacol. 1987; 21(1): 85–90.
Ibrahim Ali Omer M, Mansoub MA, Omer R, Omer R, Shadli M, Williams R. The effect of qat chewing and other factors on breast-feeding and child survival in a Yemeni society. Sudanese Journal of Paediatrics. 2011; 11(2): 14–20.
Geraghty S, Doleman G, De Leo A. Midwives' attitudes towards pregnant women using substances: Informing a care pathway. Women Birth. 2019; 32(4): 477-482. doi:10.1016/j.wombi.2018.09.007.
Economidoy E, Klimi A, Vivilaki VG. Caring for substance abuse pregnant women: The role of the midwife. Health Science Journal. 2012; 6(1): 161.
Geraghty S, Doleman G, De Leo A. Midwives' attitudes towards pregnant women using substances: Informing a care pathway. Women Birth. 2019; 32(4): 477-482. doi:10.1016/j.wombi.2018.09.007.
Stephany Theresa M. The pregnant addict: treat or prosecute?: Implications for midwifery management. Journal of Nurse-Midwifery. 1999; 44(2): 154-156.
Figurasin R, Lee VR, Maguire NJ. 3,4-Methylenedioxymethamphetamine (MDMA) Toxicity. In: StatPearls. Treasure Island (FL): StatPearls Publishing; January 17, 2024. Erişim adresi: https://www.ncbi.nlm.nih.gov/books/NBK538482/ Erişim tarihi: 18.07.2024
Baldo BA. The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns. Arch Toxicol. 2024; 98(8): 2409-2427. doi:10.1007/s00204-024-03765-8.
Sayfalar
159-186
Gelecek
22 Ocak 2025
Telif Hakkı (c) 2025 Akademisyen Yayınevi Kitap DOI Portalı
